Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Fecha
2023-01-09Referencia bibliográfica
de Almeida, R.B.M... [et al.]. Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies. Pharmaceuticals 2023, 16, 95. [https://doi.org/10.3390/ph16010095]
Patrocinador
Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB, BOL0346/2017); Programa de Pós-Graduação em Biotecnologia of Universidade Estadual de Feira de Santana (UEFS)Resumen
The enhancement of cholinergic functions via acetylcholinesterase (AChE) and butyrylcholinesterase
(BuChE) inhibition is considered a valuable therapeutic strategy for the treatment of
Alzheimer’s disease. This study aimed to evaluate the in vitro effect of ZINC390718, previously filtered
using computational approaches, on both cholinesterases and to characterize, using a molecular
dynamics (MD) simulation, the possible binding mode of this compound inside the cholinesterase
enzymes. The in vitro cytotoxicity effect was also investigated using a primary astrocyte-enriched
glial cell culture. ZINC390718 presented in vitro dual inhibitory activity against AChE at a high micromolar
range (IC50 = 543.8 M) and against BuChE (IC50 = 241.1 M) in a concentration-dependent
manner, with greater activity against BuChE. The MD simulation revealed that ZINC390718 performed
important hydrophobic and H-bond interactions with the catalytic residue sites on both
targets. The residues that promoted the hydrophobic interactions and H-bonding in the AChE target
were Leu67, Trp86, Phe123, Tyr124, Ser293, Phe295, and Tyr341, and on the BuChE target, they were
Asp70, Tyr332, Tyr128, Ile442, Trp82, and Glu197. The cytotoxic effect of Z390718, evaluated via
cell viability, showed that the molecule has low in vitro toxicity. The in vitro and in silico results
indicate that ZINC390718 can be used as chemotype for the optimization and identification of new
dual cholinesterase inhibitors.